| Issue Date |
Title |
Author(s) |
| Jun-2020 |
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study |
Huang, Jing;Xu, Jianming;Chen, Yun;Zhuang, Wu;Zhang, Yiping;Chen, Zhendong;Chen, Jia;Zhang, Helong;Niu, Zuoxing;Fan, Qingxia;Lin, Lizhu;Gu, Kangsheng;Liu, Ying;Ba, Yi;Miao, Zhanhui;Jiang, Xiaodong;Zeng, Ming;Chen, Jianhua;Fu, Zhichao;Gan, Lu;Wang, Jun;Zhan, Xianbao;Liu, Tianshu;Li, Zhiping;Shen, Lin;Shu, Yongqian;Zhang, Tao;Yang, Qing;Zou, Jianjun |
| 2015 |
Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study |
Wang, Xin;Ji, Jiafu;Zheng, Zhichao;Zhang, Helong;Zhou, Weiping;Su, Wuyun;Luo, Qi;Guo, Qunyi;Li, Xiaoyi;Tang, Yong;Xu, Jian-Ming;Tao, Feng;Li, Wei;Li, Xiaoqin;Qin, Shukui;Yu, Eric Chi-Wang;Yang, Chen;Shen, Lin |
| 2015 |
Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study |
Wang, Xin;Ji, Jiafu;Zheng, Zhichao;Zhang, Helong;Zhou, Weiping;Su, Wuyun;Luo, Qi;Guo, Qunyi;Li, Xiaoyi;Tang, Yong;Xu, Jian-Ming;Tao, Feng;Li, Wei;Li, Xiaoqin;Qin, Shukui;Yu, Eric Chi-Wang;Yang, Chen;Shen, Lin |
| 4-Oct-2022 |
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study |
Feng, Weineng;Wang, Yufeng;Ran, Fengming;Mao, Yong;Zhang, Helong;Wang, Qifeng;Lin, Wen;Wang, Zhidong;Hu, Jianli;Liao, Wangjun;Zhang, Tao;Chu, Qian;Xiong, Weijie;Yi, Tienan;Yi, Jiqun;Ma, Shoucheng;Sun, Yi;Meng, Lingzhan;Liu, Chunling;Zhou, Silang;Zheng, Dengyun;Wang, Shubin;Lin, Haifeng;Fang, Wenzheng;Li, Jun;Wu, Minhui |
| 24-Feb-2023 |
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT) |
Shi, Yuankai;Chen, Jianhua;Zhang, Helong;Zhang, Zhihong;Zhang, Yiping;Wang, Zhehai;Zhang, Shucai;Zhao, Jian;Liu, Chunling;Wang, Xiuwen;Zhao, Yanqiu;Hu, Changlu;Yang, Lei;Hao, Xuezhi;Wang, Lin;Liu, Yunpeng;Yu, Yan;Zhao, Jun;Wang, Mengzhao;Zhang, Liangming;Sun, Sanyuan;Hu, Yanping;Gu, Kangsheng;Hang, Xiaosheng;Shan, Jinlu;Zhang, Yu;Tan, Bangxian;Yang, Weihua;Yang, Runxiang;Si, Meimei;Geng, Huaize;Li, Hui;Kang, Xiaoyan |
| Aug-2021 |
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study |
Ai, Xinghao;Pan, Yueyin;Shi, Jianhua;Yang, Nong;Liu, Chunling;Zhou, Jianying;Zhang, Xiaodong;Dong, Xiaorong;He, Jianxing;Li, Xiaoling;Chen, Gongyan;Li, Xingya;Zhang, Helong;Liao, Wangjun;Zhang, Yiping;Ma, Zhiyong;Jiang, Liyan;Cui, Jiuwei;Hu, Chunhong;Wang, Wei;Huang, Cheng;Zhao, Jun;Ding, Cuimin;Hu, Xiaohua;Wang, Kai;Gao, Beili;Song, Yong;Liu, Xiaoqing;Xiong, Jianping;Liu, Anwen;Li, Junling;Liu, Zhe;Li, Yinyin;Wang, Mengzhao;Zhang, Biao;Zhang, Dan;Lu, Shun |
| 2015 |
First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation |
Shi, Yuankai;Wang, Lin;Han, Baohui;Li, Wei;Yu, Ping;Liu, Yunpeng;Ding, Cuimin;Song, Xia;Ma, Zhiyong;Ren, Xinling;Feng, Jifeng;Zhang, Helong;Chen, Gongyan;Wu, Ning;Han, Xiaohong;Yao, Chen;Song, Yong;Zhang, Shucai;Ding, Lieming;Tan, Fenlai |
| 20-May-2020 |
Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). |
Lu, Shun;Fang, Jian;Li, Xingya;Cao, Lejie;Zhou, Jianying;Guo, Qisen;Liang, Zongan;Cheng, Ying;Jiang, Liyan;Yang, Nong;Han, Zhigang;Shi, Jianhua;Chen, Yuan;Xu, Hua;Zhang, Helong;Zhang, Di;Li, Jing;Wang, Linfang;Ren, Yongxin;Su, Weiguo |
| 2019 |
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations |
Lu, Shun;Fang, Jian;Cao, Lejie;Li, Xingya;Guo, Qisen;Zhou, Jianying;Cheng, Ying;Jiang, Liyan;Chen, Yuan;Zhang, Helong;Liang, Zongan;Zhang, Xin;Wu, Biao;Shi, Jianhua;Xu, Hua;Huang, Jianjin;Yang, Zhixiong;Zeng, Shan;Hu, Yanping;Zhang, Xiaodong;Wu, Jingxun;Chen, Gongyan;Yang, Nong;Zhang, Longzhen;Fu, Yinjia;Li, Jing;Wang, Linfang;Ren, Yongxin;Su, Weiguo |
| 2019 |
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer |
Cheng, Ying;Fan, Yun;Liu, Xiaoqing;Liu, Yunpeng;Liu, Jiwei;Wang, Dong;Yu, Yan;Qin, Shukui;Liu, Wei;Huang, Cheng;Zhang, Helong;Liang, Jun;Shi, Jianhua;Sheng, Lijun;Yu, Hao |
| 1-Feb-2020 |
Treatment patterns and long-term clinical outcomes in Chinese patients with nonmetastatic gastric cancer: Results from the non-interventional EVIDENCE registry study |
Ji, Jiafu;Qin, Shukui;Wang, Xin;Zhou, Weiping;Chen, Lin;Zheng, Zhichao;Su, Wuyun;Zhang, Helong;Wang, Jianhua;Luo, Qi;Tang, Yong;Shen, Lin |
